Gilead and BioNTech Had a Great Year in 2020

In 2020, Gilead posted a turnover in Spain of $449 million (€382.7 million), 13.6% more than in the previous year, as reflected in the accounts recently presented by the company. The Spanish subsidiary’s net profit last year fell to $1.45 million (€1.24 million), compared with $2.7 million (€2.3 million) the previous year.

The context that explains these figures is the introduction in its portfolio of Veklury, a treatment against Covid-19 that was approved in 2020. The company’s worldwide data show that it had a total turnover of $2.81 billion with this drug, contributing around 11.5% of sales that year and driving revenue growth of 10% over the previous year.

Read more about Gilead and BioNTech and find the latest financial headlines with our companion app Born2Invest.

Gilead expects to bill between $2 billion and $3 billion in 2020 from the commercialization of Veklury

Gilead’s peak revenue in Spain was registered in 2015 when the company had a turnover of $1.15 billion (€978.5 million). Those figures were due to the commercialization of its hepatitis C therapies Sovaldi and Harvoni.

In 2020, Gilead also commercialized the innovative therapy Yescarta through a pay-for-results agreement set by the Ministry of Health. This treatment is based on T-cell gene therapy to treat some rare tumors. Gilead Sciences is a U.S. biotech company engaged in the research, discovery, development, and commercialization of drugs to treat diseases. The company is mainly engaged in the development of antiviral drugs to treat patients infected with HIV, hepatitis B, Covid-19, or influenza.

BioNTech expects sales of $18.6 billion (€15.9 billion) from COVID-19 vaccine in 2021

BioNTech, the German company which has developed the COVID-19 vaccine model together with Pfizer, forecasts revenues of $18.6 billion (€15.9 billion) in sales from the COVID-19 vaccine in 2021, the company said in a statement. Last year, the company posted a loss of $166.2 million (€141.7 million), but for the first six months of 2021, it posted a net profit of $4.6 billion (€3.91 billion). This turnaround in the accounts was mainly due to revenues from the coronavirus vaccine.

The German company also managed to shoot up its turnover in 2020 to $8.63 billion (€7.36 billion). This figure is equivalent to a 106-fold increase in turnover in the previous year when it posted revenue of $81.4 million (€69.4 million).

Currently, the Pfizer-BioNTech vaccine is the most widely distributed vaccine in developed countries

Ugur Sahin, CEO and co-founder of BioNTech, stressed that, together with Pfizer, the company has surpassed “one billion doses of Covid-19 vaccine shipped worldwide; a milestone achieved in six months”. The Pfizer-BioNTech vaccine was the first to be approved in the United States and the European Union (EU) in December last year and is currently the most widely distributed vaccine in developed countries.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.